GeoVax Labs, Inc. (OTC: GOVX) is a clinical-stage biotechnology company developing innovative human vaccines using its novel VLP (virus-like particle) platform technology. The company’s proprietary vaccine technology has been developed through multi-year collaborations with the U.S. National Institutes of Health, the U.S. Centers for Disease Control and Prevention and Emory University. Ultimately, its mission is to apply its expertise in areas where there is a significant unmet medical need and commercial opportunity with the goal of improving the lives of people affected by serious and life-threatening diseases. For more information, visit the company’s website at www.geovax.com.
GeoVax Labs (GOVX) Presents at Rodman & Renshaw Conference
Previous Article
Next Article
Search Articles
Latest Articles
- FAVO Capital Inc. (FAVO): When Private Credit Meets Real Estate Collateralization
- AI and the Copper Conundrum: How Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Fits into the Supply Equation
- Silvercorp Metals Inc. (NYSE-A/TSX: SVM) El Domo Environmental License Upheld as Ecuador’s Constitutional Court Dismisses Final Challenge
- NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative
- MissionIRNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $6.9 Million Public Offering Including Full Over-Allotment Option